$316.31
+1.3%West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Chief Human Resources Officer & Senior Vice President
Compensation
$545,778
Head of Investor Relations
Non-Independent Chair of the Board, President & Chief Executive Officer
Compensation
$1,586,661
President of Contract Manufacturing
Senior Advisor to the Chief Executive Officer
Compensation
$887,327
Senior Vice President & Chief Financial Officer
Compensation
$887,327
Senior Vice President & Chief Financial Officer
Senior Vice President & Chief Technology Officer
Senior Vice President and Chief Quality & Regulatory Officer
Senior Vice President of Strategy & Corporate Development
Senior Vice President, General Counsel & Company Secretary
Compensation
$583,706
Vice President of Finance & Chief Accounting Officer
During the last 12 months, insiders have sold $1.13M worth of WST shares, with no buying activity reported.
0
0.00
3.7K
1.13M
-1.1M
-$1.13M
0
0.00
0
0.00
+0
+$0
0
0.00
0
0.00
+0
+$0
0
0.00
0
0.00
+0
+$0
No buying activity
Favorite Annette F
Officer: Sr. Vp & Chief Hr Officer
$860K
Winters Chad
Officer: Vp, Chief Accounting Officer
$269K
Strong bearish signal with $1.13M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
2 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Persistent selling pressure: Consistent insider selling with weak buy/sell ratio suggests insiders may be capitalizing on current valuation. Exercise caution and review recent earnings quality and management commentary.
WST - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | March 12, 2026 | May 04, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | March 21, 2025 | May 06, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | March 13, 2024 | April 23, 2024 | 2024 | |
DEF 14A DEF 14A N/A | March 15, 2023 | March 15, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 14, 2022 | May 14, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | March 24, 2021 | May 04, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | March 25, 2020 | May 05, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | March 22, 2019 | May 07, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | March 21, 2018 | May 01, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | March 22, 2017 | May 02, 2017 | 2017 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.